未登录

D

David C. Harmon

harvard university medical affiliates

H指数:58

被引数:9,511

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Livedoid Vasculopathy: A Rare Cutaneous Extraintestinal Manifestation of Inflammatory Bowel Disease

AMERICAN JOURNAL OF GASTROENTEROLOGY

IF7.6

2024-10-010

PRE

Preadmission Metformin Use Is Associated with Reduced Mortality in Patients with Diabetes Mellitus Hospitalized with COVID-19: Metformin in Diabetes Mellitus and COVID-19

JOURNAL OF GENERAL INTERNAL MEDICINE

IF4.2

2024-09-192

PRE

Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11 (vol 7, 43941,2017)

SCIENTIFIC REPORTS

IF3.9

2024-01-220

OAAI

Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11 (vol 7, 43941, 2017)

SCIENTIFIC REPORTS

IF3.9

2018-08-091

OAAI

Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11

SCIENTIFIC REPORTS

IF3.9

2017-03-0617

OAAI

miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo

MOLECULAR ONCOLOGY

IF4.5

2016-10-2455

OAAI

Secondary Leukemia and Myelodysplastic Syndrome in 375 Patients With Ewing Sarcoma and Osteosarcoma

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2016-10-010

OAAI

Osteosarcoma of the Spine and Pelvis: One hundred fifteen Patients of a Single Institution

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2016-10-010

OAAI

NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function

BRITISH JOURNAL OF PHARMACOLOGY

IF7.7

2016-01-1528

OAAI

CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma

SCIENTIFIC REPORTS

IF3.9

2015-06-1680

OAAI

Phase 1 Study of Oral Abexinostat, a Histone Deacetylase Inhibitor, in Combination With Doxorubicin in Patients With Metastatic Sarcoma

IF5.1

2014-12-2355

OAAI

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

IF3.4

2014-11-05120

OAAI

A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells

IF3.4

2014-09-1930

OAAI

Outcomes of Patients With Synovial Sarcomas Treated With Multimodality Therapy: A Single-Institution Review

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2014-09-010

OAAI

Prognostic Factors in Alveolar Soft-Part Sarcoma: A SEER Analysis

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2014-09-010

PREAI

High-Dose Proton Beam Boosted Radiation Therapy in the Management of Non-Skull Base Chondrosarcomas

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2014-09-010

PREAI

Outcomes of Head and Neck Osteosarcoma: Ten-Year Experience at a Single Institution

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2014-09-010

OAAI

Prognostic Significance of Treatment-Induced Pathologic Necrosis in Extremity and Truncal Soft Tissue Sarcoma After Neoadjuvant Chemoradiotherapy

IF5.1

2014-07-3170

OAAI

Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925

BRITISH JOURNAL OF CANCER

IF6.8

2014-05-2245

OAAI

Effect of Adjuvant Radiation Therapy on Survival in Head and Neck Osteosarcoma

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2014-02-010

OAAI